Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins

Journal of Proteomics

Volumn 106, Issue , 2014, Pages 181-190

  Von Zychlinski, Anne ^a   Williams, Michael ^a   McCormick, Sally ^a   Kleffmann, Torsten ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Absolute protein quantification; Cardiovascular disease; Lipoproteins; Stoichiometry of apolipoproteins

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN C; APOLIPOPROTEIN E; APOLIPOPROTEIN F; BIOLOGICAL MARKER; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; PROTEOME; TRYPSIN;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; HEART DISEASE; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK FACTOR; STOICHIOMETRY; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; CLUSTER ANALYSIS; MIDDLE AGED; PROCEDURES; PROTEOMICS; YOUNG ADULT;

ADULT; AGED; APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; CLUSTER ANALYSIS; DIABETES MELLITUS; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MASS SPECTROMETRY; MIDDLE AGED; PROTEOME; PROTEOMICS; TRYPSIN; YOUNG ADULT;

EID: 84899935126     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.04.030     Document Type: Article

References (39)

1. Smith L.C., Pownall H.J., Gotto A.M. The plasma lipoproteins: structure and metabolism. Annu Rev Biochem 1978, 47:751-777.
2. Schewe T., Winkler K. Lipids and bariatric surgery. Principles of metabolic surgery 2012, 89-97. Springer Berlin Heidelberg, Berlin, Heidelberg. W.K. Karcz, O. Thomusch (Eds.).
3. Berglund L. Lipoprotein metabolism: a well-tried tool to characterize dyslipidemic mechanisms. Arterioscler Thromb Vasc Biol 2006, 26:1201-1203.
4. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. Emerging Risk Factors Collaboration.
5. Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
6. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 2006, 113:1556-1563.
7. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
8. Holme I., Aastveit A.H., Hammar N., Jungner I., Walldius G. Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Eur J Heart Fail 2009, 11:1036-1042.
9. Sun H.-Y., Chen S.-F., Lai M.-D., Chang T.-T., Chen T.-L., Li P.-Y., et al. Comparative proteomic profiling of plasma very-low-density and low-density lipoproteins. Clin Chim Acta 2010, 411:336-344.
10. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 2009, 50:S183-S188.
11. Hoofnagle A.F., Heinecke J.W. Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structures, and functions of lipoproteins. J Lipid Res 2009, 50:1967-1975.
12. Alonzi T., Mancone C., Amicone L., Tripodi M. Elucidation of lipoprotein particles structure by proteomic analysis. Expert Rev Proteomics 2008, 5:91-104.
13. Shah A.S., Tan L., Long J.L., Davidson W.S. The proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 2013, 54:2575-2585.
14. Von Zychlinski A., Kleffmann T., Williams M.J.A., McCormick S.P. Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding. J Proteomics 2011, 74:2881-2891.
15. Davidsson P., Hulthe J., Fagerberg B., Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010, 30:156-163.
16. Hoofnagle A.N., Wu M., Gosmanova A.K., Becker J.O., Wijsman E.M., Brunzell J.D., et al. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler Thromb Vasc Biol 2010, 30:2528-2534.
17. Massey J.B., Pownall H.J., Macha S., Morris J., Tubb M.R., Silva R.A.G.D. Mass spectrometric determination of apolipoprotein molecular stoichiometry in reconstituted high density lipoprotein particles. J Lipid Res 2009, 50:1229-1236.
18. Kuzyk M.A., Smith D., Yang J., Cross T.J., Jackson A.M., Hardie D.B., et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009, 8:1860-1877.
19. Flood-Nichols S.K., Tinnemore D., Wingerd M.A., Abu-Alya A.I., Napolitano P.G., Stallings J.D., et al. Longitudinal analysis of maternal plasma apolipoproteins in pregnancy: a targeted proteomics approach. Mol Cell Proteomics 2013, 12:55-64.
20. Huang R., Silva R.A.G.D., Jerome W.G., Kontush A., Chapman M.J., Curtiss L.K., et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011, 18:416-422.
21. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
22. Kettenbach A.N., Rush J., Gerber S.A. Absolute quantification of protein and post-translational modification abundance with stable isotope-labeled synthetic peptides. Nat Protoc 2011, 6:175-186.
23. Pan S., Aebersold R., Chen R., Rush J., Goodlett D.R., McIntosh M.W., et al. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 2009, 8:787-797.
24. HAVEL R.J., EDER H.A., BRAGDON J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955, 34:1345-1353.
25. Kirkpatrick D.S., Gerber S.A., Gygi S.P. The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005, 35:265-273.
26. Olsen J.V., de Godoy L.M.F., Li G., Macek B., Mortensen P., Pesch R., et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics 2005, 4:2010-2021.
27. Silva J.C., Denny R., Dorschel C.A., Gorenstein M., Kass I.J., Li G.-Z., et al. Quantitative proteomic analysis by accurate mass retention time pairs. Anal Chem 2005, 77:2187-2200.
28. Chapman M.J., Goldstein S., Lagrange D., Laplaud P.M. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 1981, 22:339-358.
29. Kontush A., Chapman M.J. Lipidomics as a tool for the study of lipoprotein metabolism. Curr Atheroscler Rep 2010, 12:194-201.
30. Scheffer P.G., Bakker S.J., Heine R.J., Teerlink T. Measurement of low-density lipoprotein particle size by high-performance gel-filtration chromatography. Clin Chem 1997, 43:1904-1912.
31. Toth P.P., Barter P.J., Rosenson R.S., Boden W.E., Chapman M.J., Cuchel M., et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 2013, 7:484-525.
32. Van Dijk K.W., van Vlijmen B.J., van't Hof H.B., van der Zee A., Santamarina-Fojo S., van Berkel T.J., et al. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE. J Lipid Res 1999, 40:336-344.
33. Jong M.C., Hofker M.H., Havekes L.M. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999, 19:472-484.
34. Pollin T.I., Damcott C.M., Shen H., Ott S.H., Shelton J., Horenstein R.B., et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008, 322:1702-1705.
35. Pillois X., Gautier T., Bouillet B., Pais de Barros J.-P., Jeannin A., Vergès B., et al. Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease. J Lipid Res 2012, 53:1200-1209.
36. Jensen M.K., Rimm E.B., Furtado J.D., Sacks F.M. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc 2012, 1. [jah3-e000232].
37. Mendivil C.O., Rimm E.B., Furtado J., Sacks F.M. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. J Am Heart Assoc 2013, 2:e000130.
38. Morton R.E., Gnizak H.M., Greene D.J., Cho K.-H., Paromov V.M. Lipid transfer inhibitor protein (apolipoprotein F) concentration in normolipidemic and hyperlipidemic subjects. J Lipid Res 2008, 49:127-135.
39. Morton R.E., Greene D.J. Conversion of lipid transfer inhibitor protein (apolipoprotein F) to its active form depends on LDL composition. J Lipid Res 2011, 52:2262-2271.